The Life Sciences team advised SpringWorks Therapeutics (Nasdaq: SWTX) on its underwritten public offering of 5,637,254 shares of its common stock at a price to the public of $51 per share, before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase up to an additional 735,294 shares of common stock. Gross proceeds from the offering were approximately $287.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
The Goodwin team was led by Kingsley Taft and included Julie Tibbets, Ettore Santucci, Elizabeth Mulkey.
For additional details on the offering, please read the press release.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
The Goodwin team was led by Kingsley Taft and included Julie Tibbets, Ettore Santucci, Elizabeth Mulkey.
For additional details on the offering, please read the press release.